Q1 Earnings Estimate for 908 Devices Issued By William Blair

908 Devices Inc. (NASDAQ:MASS - Free Report) - Stock analysts at William Blair upped their Q1 2025 earnings estimates for 908 Devices in a research report issued on Monday, March 10th. William Blair analyst M. Larew now forecasts that the company will post earnings of ($0.27) per share for the quarter, up from their prior forecast of ($0.37). The consensus estimate for 908 Devices' current full-year earnings is ($1.99) per share. William Blair also issued estimates for 908 Devices' Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.68) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.54) EPS.

MASS has been the topic of several other reports. Stephens reaffirmed an "overweight" rating and set a $6.00 target price on shares of 908 Devices in a report on Wednesday, January 15th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 908 Devices in a research note on Friday, March 7th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.33.

908 Devices Trading Up 11.4 %

Shares of NASDAQ MASS traded up $0.47 during trading on Thursday, reaching $4.58. 1,296,640 shares of the company traded hands, compared to its average volume of 921,326. The stock has a market cap of $161.81 million, a P/E ratio of -2.59 and a beta of 0.99. The firm's fifty day simple moving average is $2.69 and its 200 day simple moving average is $2.91. 908 Devices has a 12-month low of $1.81 and a 12-month high of $7.56.

Remove Ads

Hedge Funds Weigh In On 908 Devices

A number of large investors have recently bought and sold shares of MASS. Prescott Group Capital Management L.L.C. purchased a new stake in shares of 908 Devices in the fourth quarter valued at approximately $330,000. Needham Investment Management LLC increased its holdings in 908 Devices by 100.0% in the 4th quarter. Needham Investment Management LLC now owns 200,000 shares of the company's stock worth $440,000 after acquiring an additional 100,000 shares in the last quarter. AWM Investment Company Inc. increased its holdings in 908 Devices by 6.3% in the 4th quarter. AWM Investment Company Inc. now owns 1,673,924 shares of the company's stock worth $3,683,000 after acquiring an additional 99,594 shares in the last quarter. Deutsche Bank AG raised its position in 908 Devices by 1,159.4% during the fourth quarter. Deutsche Bank AG now owns 99,239 shares of the company's stock worth $218,000 after acquiring an additional 91,359 shares during the period. Finally, Bank of America Corp DE lifted its holdings in 908 Devices by 190.9% during the fourth quarter. Bank of America Corp DE now owns 94,753 shares of the company's stock valued at $208,000 after purchasing an additional 62,179 shares in the last quarter. Institutional investors and hedge funds own 88.06% of the company's stock.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.